New discovery for treatment of primary liver cancer
Posted: 19 September 2023 A preclinical study led by Monash University has discovered a drug combination with the potential to treat one of the most fatal and globally widespread cancers, a type of primary liver cancer called hepatocellular…
Mobius Medical Expands Global Footprint Into United States
Posted: 19 September 2023 Australian Contract Research Organization (CRO) Mobius Medical Expands Global Footprint, Enters United States Market, with a Strategic Focus on Medical Devices. Minneapolis, September 18, 2023 – In a strategic move to enhance its worldwide…
FDA approval for US$1.9B Australian-developed cancer treatment
Posted: 19 September 2023 A cancer drug developed in Australia has received the green light from the US Food and Drug Administration (FDA) as a bone marrow cancer treatment. Momelotinib was invented at Cytopia (ASX: CYT), an Australian…
Neo-Bionica launches onshore critical medical manufacturing process
Posted: 18 September 2023 Advanced MedTech contract manufacturer Neo-Bionica has revealed the expansion of its manufacturing services with the launch of its new hermitization capability – a first for Australian industry. Hermitization is a critical capability in the…
World-first child health study recruits 100,000 participants
Posted: 18 September 2023 A world-first study tracking the health and wellbeing of Victorians, from birth to old age, has reached a recruitment milestone of over 100,000 participants. Murdoch Children’s Research Institute’s Generation Victoria (GenV), one of the world’s largest-ever birth…
Million-dollar US Department of Defense grant for Peter Mac melanoma research
Posted: 18 September 2023 The United States Department of Defense has called on Peter Mac to help in its fight against melanoma, granting a million dollars to researcher Dr Lorey Smith. Melanoma is of particular interest to the…
World first drug to target previously untreatable life-threatening form of ‘bad cholesterol’
Posted: 28 September 2023 A new drug offers a breakthrough world-first treatment for Lipoprotein(a), a largely genetic form of cholesterol that increases the risk of heart attack and stroke. High levels of Lipoprotein(a), known as Lp(a) or spoken…
Phase 3 Common Cold Trial Results
Posted: 14 September 2023 Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) announces that trial statisticians have completed their efficacy analysis of the headline results in the Phase 3 trial of Nasodine® Nasal Spray (“Nasodine”) as a treatment for the…
Australian Good Design Awards
Posted: 14 September 2023 The Australian Good Design Awards Ceremony is the ultimate showcase of creativity, innovation and design mastery, bringing together the biggest names in the design world to celebrate the year’s best. With a black-tie atmosphere,…
Rhythm Biosciences Contracts with Nutripath on Automation Agreement
Posted: 14 September 2023 As per 31 July (Appendix 4C), transformative cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (“Rhythm” or the “Company”) is pleased to confirm it has progressed the Company’s objective to automate the ColoSTAT®…
geneType Granted Approval for Pancreatic Cancer, Melanoma, and Atrial Fibrillation in Australia
Posted: 11 September 2023 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that the expanded geneType Multi-Risk Test is now available…
New Fund Synthesis Capital to power Australia and the Asia-Pacific’s health ventures
Posted: 11 September 2023 A new pathbreaking fund to drive the growth of Australia’s medtech and deeptech health ventures is now raising. Launched this week at the 10-year celebration of the MedTech Actuator’s pathbreaking Origin program, Synthesis Capital…
